Navigation Links
MedImmune Announces Winners of the 4th Respiratory, Immunology and Autoimmunity Research Abstract Competition
Date:11/16/2009

GAITHERSBURG, Md., Nov. 16 /PRNewswire/ -- MedImmune today announced the winners of a research abstract competition highlighting the work of the next generation of scientific leaders in respiratory disease, inflammation and autoimmunity (RIA). Students and postdoctoral fellows from across the country were invited to submit abstracts on RIA research as part of a competition sponsored by MedImmune, a leading biologics company headquartered in Gaithersburg, Maryland.

The competition's ten finalists convened today at the company's headquarters to present their research to an expert panel of MedImmune judges. The three winners were announced at the awards ceremony following the presentations.

First prize of $2,000 was awarded to Eric Boilard, a postdoctoral student of Harvard Medical School and Brigham & Women's Hospital for his research on the role of platelets in amplifying inflammation in arthritis. "I would like to thank everyone at MedImmune for sponsoring this competition. I am honored to be a winner and grateful for the opportunity to receive such great feedback from renowned individuals on the panel."

Second and third prizes of $1,000 and $500 were awarded to Irving Allen of University of North Carolina and Kerstin Kiefer of Boston University School of Medicine, respectively.

"We saw some very high-caliber preclinical approaches," said Anthony J. Coyle, Ph.D., vice president, research and development and head, respiratory, inflammation and autoimmunity research at MedImmune. "Their research could pave the way for further understanding of the mechanism of these diseases, and could potentially help in the development of new therapies."

"We are committed to investing in future scientists and promoting health and science education," said Bahija Jallal, Senior Vice President of Research and Development at MedImmune. "We were impressed with today's presentations, and congratulate all of the ten finalists on their thought-provoking work."

The competition was open to graduate students and postdoctoral fellows worldwide. The expert panel of judges evaluated the abstracts according to the following criteria: scientific rationale, description of what was done, suitability of methods to aims, conclusions confirmed by objective results, ethics, scientific value, potential clinical value, originality of work and overall presentation.

Notes to Editors:

    First Place:      Harvard Medical School, Brigham & Women's Hospital
                      postdoctoral student Eric Boilard. The title of his
                      abstract is "Platelets amplify inflammation in arthritis
                      via collagen-dependent microparticle production."

    Second Place:     University of North Carolina at Chapel Hill postdoctoral
                      student Irving Allen. The title of his abstract is
                      "NLRX1 is a regulator of the innate immune response to
                      influenza A virus infection."

    Third Place:      Boston University School of Medicine postdoctoral
                      student Kerstin Kiefer. The title of her abstract is
                      "The role of TAM receptor tyrosine kinases in B cell
                      activation and differentiation."

About MedImmune

MedImmune, the worldwide biologics business for AstraZeneca PLC (LSE: AZN.L, NYSE: AZN), has approximately 3,100 employees worldwide and is headquartered in Gaithersburg, Maryland. With an advancing pipeline of promising candidates, we aim to be the next revolutionary force in biotechnology by delivering life-changing products, industry-leading performance, and a tireless commitment to improving patient health. For more information, visit MedImmune's website at www.medimmune.com.

Media Contact:

    Perla Copernik
    (301) 398-4952

SOURCE MedImmune


'/>"/>
SOURCE MedImmune
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. MedImmune Resolves FDA Observations Regarding Manufacturing Process for FluMist(R)
2. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
3. Medimmune announces phase 2 safety data for anti-RSV antibody and national RSV surveillance results
4. MedImmune to present RSV surveillance and cost-effectiveness data at American Academy of Pediatrics
5. MedImmune presents new pharmaco-economic data at AAP regarding infants at high risk for RSV
6. Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkins Lymphoma Patients
7. MedImmune Expands Scientific and Engineering Leadership
8. MedImmune Prepared to Support Implementation of Expanded ACIP Recommendations for Influenza Vaccinations
9. MedImmune Further Expands Autoimmune Disease Research Program Through Collaboration with SBI Biotech
10. MedImmune grants 5 new fellowships to help expand premature infant follow-up care research
11. Medarex to Receive Milestone Payment from MedImmune for Allowance of an Investigational New Drug Application for MEDI-546
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... ... the first technology to directly address the resolution to globally reduce the harmful ... a patented compound of FDA and TTB approved ingredients that when infused into ...
(Date:3/28/2017)... ... March 28, 2017 , ... Resoundant, Inc., the developer of ... Siemens Healthineers annual customer education symposium, a world-class learning conference that offers educational ... 27 - 31, 2017 at the Atlanta Marriott Marquis in Atlanta, Georgia. , ...
(Date:3/28/2017)... ... March 29, 2017 , ... The Thyroid Secret is a ... FASCP. The program was recently launched on March 1, and Dr. Wentz discussed ... , Dr. Izabella Wentz is a licensed pharmacist and a foremost thyroid ...
(Date:3/28/2017)... Seattle, WA (PRWEB) , ... March 28, 2017 ... ... reach a 22% share of all holidays (IBT World Travel Trends Report). As ... physically challenging, include a range in temperatures, and prolonged sun exposure. In response, ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... advancing the science and clinical practice of radiosurgery, announced today the publication ... multi-institutional, observational registry established to standardize data collection from patients treated with ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... 2017 The global emerging cancer diagnostics market ... from 2016 to 2023 and reach a figure of ... is a chronic disease and is affecting a huge ... market. This report is focused on emerging cancer diagnostics ... is propelled due to factors such as: increasing number ...
(Date:3/28/2017)... 2017  Medeon Biodesign, Inc., a ... to announce that the Company led and successfully ... Inc., a San Jose, CA ... orthopedic extremity applications.  The orthopedic ... due to procedure volume growth, lifestyle influences and ...
(Date:3/28/2017)... -- "US Cancer Generics Market Outlook 2022" report gives ... analysis related to the emergence and integration of ... US. The report analyzes various clinical and non-clinical ... drugs in recent years. The introduction of generics ... for various stake holders involved US cancer drug ...
Breaking Medicine Technology: